



PharmaFacts for Case Managers

September 2025

Brought to you by the publishers of **CareManagement**

Dawnzera Injection

- *Generic Name:* Donidalorsen.
- *Company:* Ionis Pharmaceuticals, Inc.
- *Treatment For:* Prophylaxis to prevent attacks of hereditary angioedema in adult and pediatric patients 12 years of age and older.
- *Description:* A prekallikrein-directed antisense oligonucleotide (ASO) covalently linked to a ligand containing three N-acetylgalactosamine residues to facilitate delivery of the ASO to hepatocytes.
- *Drug Class:* Antisense oligonucleotide.
- *Dosing Information:* Dawnzera 80 mg administered subcutaneously every 4 weeks (80 mg every 8 weeks may be considered).
- *Side Effects:* Injection-site reactions, upper respiratory tract infections, urinary tract infection, and abdominal discomfort.
- *Full Prescribing Information:* <https://ionis.com/medicines/DAWNZERA/DAWNZERA-FPI.pdf>

Tonmya

- *Generic Name:* Cyclobenzaprine hydrochloride.
- *Company:* Tonix Pharmaceuticals Holding Corp.
- *Treatment For:* Fibromyalgia in adults.
- *Description:* Tonmya is a white to off-white crystalline tricyclic amine salt powder.
- *Dosing Information:* Tonmya is administered 5.6 mg sublingually once daily at bedtime.
- *Side Effects:* Embryofetal toxicity, serotonin syndrome, CNS depression, oral mucosal reactions, atropine-like adverse reactions, tricyclic antidepressant-like reactions.
- *Full Prescribing Information:* <https://www.tonixpharma.com/wp-content/uploads/2025/08/Tonmya-Prescribing-Information.pdf>

Papzimeos Injection

- *Generic Name:* Zopapogene imadenovec-drba.
- *Company:* Precigen, Inc.
- *Treatment For:* Recurrent respiratory papillomatosis in adults.
- *Description:* Papzimeos is a non-replicating adenoviral vector-based immunotherapy designed to express a fusion antigen of selected regions of human papillomavirus problems expressed in HPV-6 and HPV-11 infected cells.
- *Drug Class:* Immunotherapy.
- *Dosing Information:* Papzimeos is administered in 5 x 10¹¹ particle units per subcutaneous injection four times over a 12-week interval.
- *Side Effects:* Injection-site reaction, thrombotic events, oral paresthesia and pain, fatigue, chills, pyrexia, myalgia, and nausea.
- *Full Prescribing Information:* <https://precigen.com/papzimeos-prescribing-information.pdf>

Brinsupri Tablets

- *Generic Name:* Brensocatib.
- *Company:* Ismed Incorporated.
- *Treatment For:* Non-cystic fibrosis bronchiectasis in adults and pediatric patients 12 years and older.
- *Description:* Brinsupri is a competitive, reversible inhibitor of dipeptidyl peptidase that activates pro-inflammatory neutrophil serine proteases during neutrophil maturation in the bone marrow.
- *Drug Class:* Immunotherapy.
- *Dosing Information:* 10 mg or 25 mg orally once a day.
- *Side Effects:* Dermatologic reactions, upper respiratory tract infections, headache, and hypertension.
- *Full Prescribing Information:* https://insmed.com/pdf/brinsupri_full_prescribing_information.pdf



Hernexeos Tablets

- *Generic Name:* Zongertinib tablets.
- *Company:* Boehringer Ingelheim Pharmaceuticals, Inc.
- *Treatment For:* Adults with unresectable or metastatic, non-squamous non-small cell lung cancer tyrosine kinase domain-activating mutations and who have received prior systemic therapy.
- *Description:* Hernexeos is a kinase inhibitor of human epidermal growth factor receptor 2 (HER2).
- *Drug Class:* Chemotherapy.
- *Dosing Information:* Dosing is based on weight: < 90 kg: 120 mg; > 90 kg: 180 mg taken once a day until disease progression or unacceptable toxicity.
- *Side Effects:* Hepatotoxicity, left ventricular dysfunction, interstitial lung disease/pneumonitis, gastrointestinal disorders, skin disorders.
- *Full Prescribing Information:* <https://pro.boehringer-ingelheim.com/us/products/hernexeos/bipdf/hernexeos-prescribing-information>

Modeyso Capsules

- *Generic Name:* Dordaviprone.
- *Company:* Jazz Pharmaceuticals, Inc.
- *Treatment For:* Adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.
- *Description:* Modeyso is a protease activator.
- *Dosing Information:* Recommended dose for adults is 625 mg orally once a week. The recommended dose for pediatric patients ³ 10 kg is based on weight. Continue dosing until disease progression or until unacceptable toxicity.
- *Side Effects:* Hypersensitivity, QTc interval prolongation, fatigue, nervous system disorders, gastrointestinal disorders.
- *Full Prescribing Information:* <https://pp.jazzpharma.com/pi/modeyso.en.USPI.pdf> 